Poor
Poorly Aligned
Patient Risk:
Low
Summary
All extracted statements concern insurance coverage, pharmacy dispensing, or prescriber refill practices and are absent from the supplied prescribing information. None directly contradicts the label, but the response is not supported by the provided label.
Category Scores
Accurate Statements
Unsupported Statements
Vascepa's maximum refill limit cannot be determined without the patient's insurer and plan details.
This statement is absent from the supplied prescribing information.
Vascepa refill limits are set by the specific prescription benefit design.
This statement is absent from the supplied prescribing information.
Vascepa refill limits may include a 90-day supply maximum, quantity limits, or a maximum number of refills within 12 months.
These refill-limit examples are absent from the supplied prescribing information.
Vascepa refill limits can vary among commercial insurance, Medicare Part D, Medicaid, and employer plans.
This statement is absent from the supplied prescribing information.
Some insurance plans apply quantity or days-supply limits to Vascepa instead of specifying a maximum number of refills.
This statement is absent from the supplied prescribing information.
A Vascepa refill limit may be enforced through the prescription label or pharmacy system.
This statement is absent from the supplied prescribing information.
Vascepa prescriptions may commonly be dispensed as 30-day or 90-day supplies.
The supplied prescribing information does not state these dispensing durations.
The number of Vascepa refills remaining may be limited by the insurance plan or by the prescriber.
This statement is absent from the supplied prescribing information.
Contradictions
Important Omissions
The response should have clarified that the supplied prescribing information does not specify a maximum refill limit or insurance-plan refill rules.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements are not supported by the supplied label, but they do not provide dosing changes, administration instructions, or other direct treatment guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Poorly Aligned
Primary Issue
The response makes multiple insurance, dispensing, and refill-policy claims that are absent from the supplied prescribing information.
Suggested Improvement
State that the prescribing information does not establish a maximum refill limit and avoid presenting insurance, pharmacy, or prescriber refill rules as label-supported facts.